688176 Jiangsu Yahong Meditech
- 6.67
- +0.29+4.55%
Jiangsu Yahong Meditech News
Yahong Pharmaceutical (688176.SH)'s revenue in the first quarter increased 126% month-on-month
On April 29, Yahong Pharmaceutical (stock code: 688176.SH) released its report for the first quarter of 2024. The company achieved revenue of 243.195 million yuan in the first quarter, an increase of 126.08% over the previous quarter. This was mainly due to the company's sales of commercial products, pezopanib tablets (trade name: Dipite) and neratinib maleate tablets (trade name: OUBI) during the reporting period. Depat and Oubi went on sale in October and December 2023 respectively, and product sales increased in the first quarter of this year.
Yahong Pharmaceutical (688176): APL-1702NDA is expected soon to be commercialized
Incident: The company released its 2023 annual report. During the reporting period, it achieved operating income of 13.753 million yuan, R&D investment of 360 million yuan (+49.5%), monetary capital and transactional financial assets of about 2.33 billion yuan, and capital reserves
Yahong Pharmaceutical (688176.SH) announced 2023 annual results, all core products are under development, and net loss increased to 400 million yuan
Yahong Pharmaceutical (688176.SH) disclosed its 2023 annual report. The company achieved revenue of 13.7533 million yuan during the reporting period, an increase of 52,604.25% over the previous year. The net loss attributable to shareholders of listed companies was 400 million yuan, and the net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 432 million yuan. The loss increased year-on-year.
Yahong Pharmaceutical: Significant revenue growth in 2023 Core product APL-1702? New drug marketing applications are expected to be accepted in Q2
Gelonghui, April 17 | Yahong Pharmaceutical released its annual report. In 2023, the company achieved operating income of 13.7533 million yuan, an increase of 137.272 million yuan over the same period last year. The revenue growth was mainly due to sales revenue and license fee revenue generated by prazopanib tablets and neratinib maleate tablets in Q4 of 2023. In addition, the company's core products have made many advances. For example, APL-1702 is actively preparing to submit a new drug marketing application, and Q2 is expected to be accepted; APL-1706's new drug marketing application has been accepted; and APL-1202 and PD-1's phase II clinical trial analysis has been positive
Yahong Pharmaceutical (688176.SH): APL-1706 has reached the main research endpoint of phase III clinical trials. The application for marketing has been accepted
Yahong Pharmaceutical (688176.SH) issued an announcement. The results of the company's APL-1706 multi-center clinical trial for bladder cancer diagnosis were selected for the 39th European Urological Medical Association (EAU) in 2024, and phase III clinical trial data was released in the form of an oral report. APL-1706 is currently the only developer drug approved in the world to aid bladder cancer diagnosis or surgery. Through combined use with a blue light cystoscope, it can effectively improve the detection rate of bladder cancer (especially the detection rate of cancer in situ (CIS)), make surgical resection more complete, thereby reducing the recurrence rate of tumors.
Phase III clinical data for the world's first proven cervical HSIL non-surgical treatment product released
Gelonghui, March 18 | Yahong Pharmaceutical announced the results of the APL-1702 international multi-center phase III clinical trial of its non-surgical treatment of high-grade cervical squamous intraepithelial lesion (HSIL) products, showing that in terms of main efficacy endpoints, the response rate of the APL-1702 group increased by 89.4% compared to the placebo control group, showing significant curative effects. At the same time, APL-1702 increased clearance of high-risk HPV16 and/or HPV18, and the APL-1702 group increased 103.9% compared to the control group. Two groups of TRAE (treatment-related adverse events) and SAE (serious adverse events)
Yahong Pharmaceutical (688176.SH): Release of APL-1702 international multi-center phase III clinical trial data for the treatment of high-grade squamous intraepithelial lesion of the cervix
Gelonghui, March 18 | Yahong Pharmaceutical (688176.SH) announced that recently, Jiangsu Yahong Pharmaceutical Technology Co., Ltd. product APL1702 for treating high-grade cervical squamous intraepithelial lesion (HSIL) prospective, randomized, double-blind, placebo-controlled international multi-center phase III clinical trial results were selected for the 2024 European Genital Infection and Oncology Research Organization Conference (EUROGIN) and 2024 American Gynecological Oncology Society Annual Meeting (SGO), and
While Institutions Invested in Jiangsu Yahong Meditech Co., Ltd. (SHSE:688176) Benefited From Last Week's 10% Gain, Retail Investors Stood to Gain the Most
Key Insights The considerable ownership by retail investors in Jiangsu Yahong Meditech indicates that they collectively have a greater say in management and business strategy 50% of the business is
Yahong Pharmaceutical (688176.SH): A total cost of 8.142,100 yuan to buy back 0.2325% of the shares
Gelonghui, Feb. 29丨Yahong Pharmaceutical (688176.SH) announced that as of February 29, 2024, the company had repurchased a total of 1,325,215 shares, accounting for 0.2325% of the company's total share capital. The highest price of the repurchase transaction was RMB 6.66 yuan/share, the lowest price was RMB 5.33 yuan/share, and the total amount of capital paid was RMB 8.1421 million.
Yahong Pharmaceutical (688176.SH) Performance Report: Net loss of 400 million yuan in 2023
Gelonghui, Feb. 23 | Yahong Pharmaceutical (688176.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 13.7533 million yuan; net profit attributable to owners of the parent company was -400 million yuan, with net loss increasing year-on-year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss was -432.5 million yuan, with net loss increasing year-on-year after deduction.
Yahong Pharmaceutical will announce the APL-1702 international multi-center phase III clinical trial data of its non-surgical cervical HSIL product at SGO in 2024
SHANGHAI, Feb. 23, 2024/PRNewswire/ -- Yahong Pharmaceutical (stock code: 688176.SH), a global innovative pharmaceutical company focusing on urogenital tumors, recently announced that the results of the APL-1702 international multi-center phase III clinical trial of its non-surgical treatment of cervical HSIL product were selected for the American Society of Gynecologic Oncology (SGO) Late Breaking Oral Presentation (SGO) held on March 16-18, 2024, and will release clinical trial data in the form of an oral report. Oral Report: APL-170
Jiangsu Yahong Meditech to Buy Back Shares for Up to 100 Million Yuan
Jiangsu Yahong Meditech (SHA:688176) plans to repurchase shares for a consideration of between 50 million yuan and 100 million yuan through centralized bidding on the Shanghai Stock Exchange. Each sha
Express News | Ten listed companies announced plans with a maximum repurchase amount of 100 million yuan after the market. Follett and Juhe Materials all plan to repurchase shares of up to 600 million yuan
Yahong Pharmaceutical (688176.SH): Initial repurchase of 182,800 shares
Gelonghui, February 8, 丨 Yahong Pharmaceutical (688176.SH) announced that on February 8, 2024, the company repurchased 182,800 shares for the first time through the Shanghai Stock Exchange trading system, accounting for 0.0321% of the company's total share capital. The highest price of the repurchase transaction was RMB 5.52 per share, the lowest price was RMB 5.33 yuan/share, and the total capital paid was RMB 999,176.00 (excluding transaction fees such as stamp duty and transaction fees).
Express News | Yahong Pharmaceutical: Plans to buy back shares for 50 million yuan to 100 million yuan
Yahong Pharmaceutical (688176): ACCRUE study did not reach the main end point, APL-1702 is expected to submit an NDA in 24Q2
Incident: On February 4, 2024, the company announced the use of APL-1202 in combination with chemotherapeutic perfusion to treat recurrent middle- and high-risk non-muscle-invasive bladder cancer (NMIBC) with chemotherapy perfusion for randomized, double-blind, controlled, multicenter
Dragon Tiger List | Cambridge Technology was sold for 155 million yuan, and 4 institutions fled Yahong Pharmaceutical for more than 69 million yuan
The top three net sales in today's Dragon Tiger list are Cambridge Technology, Nongshang Environmental, and Yahong Pharmaceutical
A-share changes | Yahong Pharmaceutical fell to a record low and terminated the development of APL-1202 in combination with chemotherapy
Gelonghui Feb. 5 | Yahong Pharmaceutical (688176.SH) dropped to 5.2 yuan in 20CM, a record low, with a total market value of 2,964 billion yuan. On the evening of February 4, Yahong Pharmaceutical announced that key clinical trial data on the company's product APL-1202 combined with chemotherapy infusion to treat recurrent medium- and high-risk non-muscle-invasive bladder cancer (NMIBC) with second-line chemotherapy perfusion showed that stratification according to current guidelines showed a certain trend in event-free survival among high-risk NMIBC patients, but the trial did not reach the main research end point. The company decided to terminate the partnership between APL-1202 and chemotherapy injections
Express News | Yahong Pharmaceutical: APL-1202 data released, will continue to explore the field of bladder cancer and expand more possibilities in the future
Yahong Pharmaceutical (688176.SH): Discontinuing the combined use of APL-1202 and chemotherapy perfusion in the further development of related indications
Gelonghui, Feb. 4: Yahong Pharmaceutical (688176.SH) announced that recently, a key randomized, double-blind, controlled, multi-center clinical trial of the company's product APL1202 combined with chemotherapy infusion to treat medium- and high-risk non-muscle-invasive bladder cancer (NMIBC) recurrent with chemotherapy perfusion has been completed. Statistical analysis results showed that although showing a certain trend of efficacy among some patients, this study did not reach the main study end point, and the company decided to stop further development of APL-1202 in combination with chemotherapy infusion for this indication. As of December 31, 2023, APL-
Analysis
Price Target
No Data
